Mycophenolate mofetil reduces myofibroblast infiltration and collagen III deposition in rat remnant kidney

Kidney International

Volumn 58, Issue 1, 2000, Pages 51-61

  Badid, Chérif ^a,b   Vincent, Madeleine ^a,b   McGregor, Brigitte ^a,b   Melin, Martine ^a,b   Hadj Aissa, Aoumeur ^a,b   Veysseyre, Cécile ^a,b   Hartmann, Daniel J ^a,b   Desmouliere, Alexis ^a,b   Laville, Maurice ^a,b  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

Cell proliferation; Chronic renal disease; Fibrosis; Subtotal nephrectomy; smooth muscle actin

Indexed keywords

ALPHA ACTIN; COLLAGEN TYPE 3; CYCLINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; COLLAGEN SYNTHESIS; CONTROLLED STUDY; EXTRACELLULAR MATRIX; KIDNEY FAILURE; KIDNEY FIBROSIS; KIDNEY INJURY; MYOFIBROBLAST; NEPHRECTOMY; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; RAT;

EID: 0033920978     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2000.00140.x     Document Type: Article

References (37)

1. 1. DARBY I, SKALLI O, GABBIANI G: α-Smooth muscle actin is transiently expressed by myofibroblasts during experimental wound healing. Lab Invest 63:21-29, 1990
2. 2. KOVACS EJ: Fibrogenic cytokines: The role of immune mediators in the development of scar tissue. Immunol Today 12:17-23, 1991
3. 3. ONG ACM, FINE LG: Tubular derived growth factors and cytokines in the pathogenesis of tubulointerstitial fibrosis: Implications for human renal disease progression. Am J Kidney Dis 23:205-209, 1994
4. 4. CORTES P, ZHAO X, RISER BL: Role of glomerular mechanical strain in the pathogenesis of diabetic nephropathy. Kidney Int 51:57-68, 1997
5. 5. GABBIANI G: The biology of the myofibroblast. Kidney Int 41:530-532, 1992
6. 6. GRINELL F: Fibroblasts, myofibroblasts and wound contraction. J Cell Biol 124:401-404, 1994
7. 7. SKALLI O, ROPRAZ P, TRZECIAK A, BENZONANA G, GILLESSEN D, GABBIANI G: A monoclonal antibody against α-smooth muscle actin: A new probe for smooth muscle differentiation. J Cell Biol 103:2787-2796, 1986
8. 8. EUROPEAN MYCOPHENOLATE MOFETIL COOPERATIVE STUDY GROUP: Placebo-controlled study of mycophenolate mofetil combined with cyclosporine and corticosteroids for prevention of acute rejection. Lancet 345:1321-1325, 1995
9. 9. KOBASHIGAWA J, MILLER L, RENLUND D, MENTZER R, ALDERMAN E, BOURGE R, COSTANZO M, EISEN H, DUREAU G, RATKOVEC R, HUMMEL M, IPE D, JOHNSON J, KEOGH A, MAMELOK R, MANCINI D, SMART F, VALANTINE H: A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Transplantation 66:507-515, 1998
10. 10. O'HAIR DP, MCMANUS RP, KOMOROWSKI R: Inhibition of chronic vascular rejection in primate cardiac xenografts using mycophenolate mofetil. Ann Thorac Surg 58:1311-1315, 1994
11. 11. GREGORY CR, PRATT RE, HUIE P, SHORTHOUSE R, DZAU VJ, BILLINGHAM ME, MORRIS RE: Effects of treatment with cyclosporine, FK506, rapamycin, mycophenolic acid or desoxyspergualin on vascular muscle proliferation in vitro and in vivo. Transplant Proc 25:770-771, 1993
12. 12. GREGORY CR, HUANG X, PRATT RE, DZAU VJ, SHORTHOUSE R, BILLINGHAM ME, MORRIS RE: Treatment with Rapamycin and mycophenolic acid reduces arterial intimal thickening produced by mechanical injury and allows endothelial replacement. Transplantation 59:655-661, 1995
13. 13. MOHACSI PJ, TULLER D, HULLIGER B, WIJNGAARD PLJ: Different inhibitory effects of immunosuppressive drugs on human and rat aortic smooth muscle and endothelial cell proliferation stimulated by platelet-derived growth factor or endothelial cell growth factor. J Heart Lung Transplant 16:484-492, 1997
14. 14. SHIMAMURA T, MORRISON AB: A progressive glomerulosclerosis occurring in partial five-sixths nephrectomy. Am J Pathol 79:95-101, 1975
15. 15. WEIBEL ER: Stereological methods, in Practical Methods for Biological Morphometry, vol 1, edited by WEIBEL ER, London, Academic Press, 1979, pp 51-57
16. 16. MILLER PL, RENNKE HG, MEYER TW: Glomerular hypertrophy accelerates hypertensive glomerular injury in rats. Am J Physiol 261:F459-F465, 1991
17. 17. VIALLE-PRESLES MJ, HARTMANN DJ, FRANC S, HERBAGE D: Immunohistochemical study of the biological fate of subcutaneous bovine collagen implant in rat. Histochemistry 91:177-184, 1989
18. 18. POSTON RN, HASKARD DO, COUCHER JR, GALL NP, JOHNSON-TIDEY RR: Expression of intercellular adhesion molecule-1 in atherosclerotic plaques. Am J Pathol 140:665-673, 1992
19. 19. YANAGISAWA M, IMAI H, FUKUSHIMA Y, YASUDA T, MIURA AB, NAKAMOTO Y: Effects of tumor necrosis alpha and interleukin 1 beta on the proliferation of cultured glomerular epithelial cells. Virchows Arch 424:581-586, 1994
20. 20. MUCHANETA-KUBARA EC, EL NAHAS AM: Myofibroblast phenotypes expression in experimental renal scarring. Nephrol Dial Transplant 12:904-915, 1997
21. 21. KLEINKNECHT C, TERZI F, BURTIN M, LAOUARI D, MANIAR S: Experimental models of nephron reduction: Some answers, many questions. Kidney Int 47(Suppl 49):S51-S54, 1995
22. 22. GRIFFIN KA, PICKEN M, BIDANI AK: Method of renal mass reduction is a critical modulator of subsequent hypertension and glomerular injury. J Am Soc Nephrol 4:2023-2031, 1994
23. 23. REMUZZI G, ZOJA C, GAGLIARDINI E, CORNA D, ABBATE M, BENIGNI A: Combining an antiproteinuric approach with mycophenolate mofetil fully suppresses progressive nephropathy of experimental animals. J Am Soc Nephrol 10:1542-1549, 1999
24. 24. NG YY, HUANG TP, YANG WC, CHEN ZP, YANG AH, MU W, NIKOLIC-PATERSON DJ, ATKINS RC, LAN HY: Tubular epithelial-myofibroblast transdifferentiation in progressive tubulointerstitial fibrosis in 5/6 nephrectomized rats. Kidney Int 54:864-876, 1998
25. 25. ZHANG K, REKHTER MB, GORDON D, PHAN SH: Myofibroblasts and their role in lung collagen gene expression during pulmonary fibrosis: A combined immunohistochemical and in situ hybridization. Am J Pathol 145:114-125, 1994
26. 26. TANG WW, VAN GY, QI M: Myofibroblast and α(III) collagen expression in experimental tubulointerstitial nephritis. Kidney Int 51:926-931, 1997
27. 27. FUJIHARA CK, AVANCINI DM, COSTA MALHEIROS DMA, DE ZATZ R, LOURDES NORONHA I: Mycophenolate mofetil attenuates renal injury in the rat remnant kidney. Kidney Int 54:1510-1519, 1998
28. 28. ROMERO F, RODRIGUEZ-lTURBE B, PARRA G, GONZALES L, HERRERA-ACOSTA J, TAPIA E: Mycophenolate mofetil prevents the progressive renal failure induced by 5/6 renal ablation in rats. Kidney Int 55:945-955, 1999
29. 29. CATTEL V: Macrophages in acute glomerular inflammation. Kidney Int 45:945-952, 1994
30. 30. DESMOULIÈRE A, GEINOZ A, GABBIANI F, GABBIANI G: TGF-β1 induces α-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts. J Cell Biol 122:103-111, 1993
31. 31. TANG WW, ULICH TR, LACEY DL, HILL DC, QI M, KAUFMAN SA, VAN GY, TARPLEY JE, YEE JS: Platelet-derived growth factor-BB induces renal tubulointerstitial myofibroblast formation and tubulointerstitial fibrosis. Am J Pathol 148:1169-1180, 1996
32. 32. HAUSER IA, RENDERS L, RADEKE HH, STERZEL RB, GOPPELT-STRUEBE M: Mycophenolate mofetil inhibits rat and human mesangial cell proliferation by guanosine depletion. Nephrol Dial Transplant 14:58-63, 1999
33. 33. GOUMENOS DS, BROWN CB, SHORTLAND J, EL NAHAS AM: Myofibroblasts, predictors of progression of mesangial IgA nephropathy. Nephrol Dial Transplant 9:1418-1425, 1994
34. 34. BADID C, DESMOULIÈRE A, MCGREGOR B, COSTA AMA, FOUQUE D, HADJ AISSA A, LAVILLE M: Interstitial α-smooth muscle actin: A prognostic marker in membranous nephropathy. Clin Nephrol 52:210-217, 1999
35. 35. NOWACK R, BIRCK R, VAN DER WOUDE FJ: Mycophenolate mofetil for systemic vasculitis and IgA nephropathy. Lancet 349:774, 1997
36. 36. BRIGGS WA, CHOI MJ, SCHEEL PJ: Successful mycophenolate mofetil treatment of glomerular disease. Am J Kidney Dis 31:213-217, 1998
37. 37. SOLLINGER HW, DEIERHOI MH, BELZER FO, DIETHELM AG, KAUFFMAN RS: RS46143: A phase I trial and pilot rescue study. Transplantation 53:428-432, 1992